Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane A Foster

Showing results (111-120 of 132) with videos related to

Pageof 14
Sort By:
Translational Psychiatry|October 10, 2019
Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressantsChelsey Ju, Laura M Fiori, Raoul Belzeaux, et al.
Molecular Psychiatry|November 10, 2021
Diet and depression: future needs to unlock the potentialWolfgang Marx, Melissa M Lane, Meghan Hockey, et al.
Translational Psychiatry|October 12, 2024
Modulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression studyBenjamin Schwartzmann, Raaj Chatterjee, Yasaman Vaghei, et al.
Scientific Reports|September 15, 2023
A standardized workflow for long-term longitudinal actigraphy data processing using one year of continuous actigraphy from the CAN-BIND Wellness Monitoring StudyAnastasiya Slyepchenko, Rudolf Uher, Keith Ho, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 30, 2020
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) ReportKatharine Dunlop, Sakina J Rizvi, Sidney H Kennedy, et al.
Nature Communications|April 4, 2020
GPR56/ADGRG1 is associated with response to antidepressant treatmentRaoul Belzeaux, Victor Gorgievski, Laura M Fiori, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 5, 2023
Influence of <i>CYP2C19</i>, <i>CYP2D6</i>, and <i>ABCB1</i> Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) StudyFarhana Islam, Leen Magarbeh, Samar S M Elsheikh, et al.
JAMA Psychiatry|February 11, 2026
One-Year Actigraphy Study of Sleep and Rest-Activity Rhythms as Markers of Relapse in DepressionAndre C Tonon, Adile Nexha, Jasmyn E A Cunningham, et al.
Translational Psychiatry|February 16, 2021
Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant responseVictoria S Marshe, Malgorzata Maciukiewicz, Anne-Christin Hauschild, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|March 29, 2025
Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l'aide des scores de risque polygéniques : Rapport sur l'étude CAN-BIND-1Leen Magarbeh, Samar S M Elsheikh, Farhana Islam, et al.
Pageof 14

Showing results (111-120 of 132) with videos related to

Sort By:
Pageof 14
Translational Psychiatry|October 10, 2019
Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressantsChelsey Ju, Laura M Fiori, Raoul Belzeaux, et al.
Molecular Psychiatry|November 10, 2021
Diet and depression: future needs to unlock the potentialWolfgang Marx, Melissa M Lane, Meghan Hockey, et al.
Translational Psychiatry|October 12, 2024
Modulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression studyBenjamin Schwartzmann, Raaj Chatterjee, Yasaman Vaghei, et al.
Scientific Reports|September 15, 2023
A standardized workflow for long-term longitudinal actigraphy data processing using one year of continuous actigraphy from the CAN-BIND Wellness Monitoring StudyAnastasiya Slyepchenko, Rudolf Uher, Keith Ho, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 30, 2020
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) ReportKatharine Dunlop, Sakina J Rizvi, Sidney H Kennedy, et al.
Nature Communications|April 4, 2020
GPR56/ADGRG1 is associated with response to antidepressant treatmentRaoul Belzeaux, Victor Gorgievski, Laura M Fiori, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 5, 2023
Influence of <i>CYP2C19</i>, <i>CYP2D6</i>, and <i>ABCB1</i> Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) StudyFarhana Islam, Leen Magarbeh, Samar S M Elsheikh, et al.
JAMA Psychiatry|February 11, 2026
One-Year Actigraphy Study of Sleep and Rest-Activity Rhythms as Markers of Relapse in DepressionAndre C Tonon, Adile Nexha, Jasmyn E A Cunningham, et al.
Translational Psychiatry|February 16, 2021
Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant responseVictoria S Marshe, Malgorzata Maciukiewicz, Anne-Christin Hauschild, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|March 29, 2025
Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l'aide des scores de risque polygéniques : Rapport sur l'étude CAN-BIND-1Leen Magarbeh, Samar S M Elsheikh, Farhana Islam, et al.
Pageof 14